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ABSTRACT 
Objective: In order to investigate the human plasma pharmacokinetics of dFdC, the objective of this work was to optimize and validate a rapid 
reversed-phase (RP) high-performance liquid chromatography (HPLC) method according to the guidelines of the international regulatory 
institutions: European Medicines Agency (EMA), Food and Drug Administration (FDA) and International Conference on Harmonization (ICH). 
Methods: Chromatographic runs were performed on a RP-ACE-C18 column. Mobile phase was constituted of sodium acetate buffer (pH 5) and 
acetonitrile, in gradient mode, at a flow rate of 1 mL/min. Gemcitabine and cytarabine (internal standard) were detected at 290 nm.  
Results: The method was shown to be selective, linear in the range of 0.25–10 mg/L (R2=0.9998), accurate and precise within-run and between-run 
as reflected by the coefficient of variation values (<15%) and the relative errors values (<15%), stable and robust to changes in the column 
temperature and detection UV wavelength. Detection limit and lower limit of quantification were 0.22 and 0.25 mg/L respectively. Conclusion: The 
developed method is useful to measuring gemcitabine plasmatic concentrations in pharmacokinetics studies and in therapeutic drug monitoring. 
Keywords: Gemcitabine, Cytarabine, Reversed-phase HPLC,
 
 Plasma.  
INTRODUCTION 
Gemcitabine (dFdC, 2',2'–difluorodeoxycytidine) is a deoxycytidine 
nucleoside analogue of deoxycytidine (pyrimidine antimetabolite), 
with a wide spectrum of antitumor activities. It is broadly used for 
standard treatment in pancreatic cancer, tumors of the lung, breast, 
and bladder, renal cell carcinoma, and cancer of the biliary tract 
either as a single drug or in combination with other cytotoxic agents. 
It is one of the reference drugs used in combination chemotherapy of 
NSCLC[1-7]. Comparing with deoxycytidine, two fluorine atoms have 
been inserted into the deoxyribose ring (Figure 1) and like other 
nucleoside analogues, gemcitabine 
 
Fig. 1: Chemical structure of gemcitabine (2’,2’-
difluorodeoxycytidine) 
 
Gemcitabine cellular influx occurs via de nucleoside transport 
system and undergoes intracellular phosphorylation by 
deoxycytidine kinase to form 2’,2’-difluoro-2-deoxycytidine 5-
monophosphate (dFdCMP), 2’,2’-difluoro-2-deoxycytidine 5-
diphosphate (dFdCDP), and 2’,2’-difluoro-2-deoxycytidine 5-
triphosphate (dFdCTP). dFdCDP and dFdCTP are responsible for the 
cytotoxic effects of gemcitabine. Gemcitabine is deaminated to the 
inactive metabolite 2’,2’-difluorodeoxyuridine (dFdU) by cytidine 
deaminase [3,5,8-13]. 
is a pro-drug: it is inactive in its 
original form, depending on the intracellular machinery to gain 
pharmacological activity [5,7,8]. 
Gemcitabine is usually administered at a dose of 1000 mg/m2, by 
intravenous infusion, at a fixed dose rate of 10 mg/m2/min, for 30 
min, on days 1 and 8 of a 21 days treatment cycle. Previous studies 
suggested that the dFdCTP accumulation rate is saturated at a 
gemcitabine plasma concentration of 15–20 μM [4,11,12] and 
alternative doses and treatment schemes have been evaluated in 
order to optimize therapeutic efficacy of gemcitabine [9,11,12]. 
However, these schemes, basedon low infusion rates over prolonged 
time periods or ona low dose application of the drug, led to low 
plasmaconcentrations of gemcitabine and dFdU [11]. 
A recent systematic review and meta-analysis of all randomized 
controlled trials that compared the efficacy of doublet versus single 
third-generation cytotoxic agent as first-line treatment for elderly 
patients with advanced non-small-cell lung cancer (NSCLC) revealed 
that the use of gemcitabine in combination with other cytotoxic 
agents (doublet therapy) was superior to a single third-generation 
cytotoxic agent [14]. Nevertheless, drug dosage and treatment 
schedulesare still not optimized. Moreover, and although 
gemcitabine hydrochloride is considered as a relatively safe 
cytotoxic agent, caution is required due to the risk of induced lung 
injury and death[15]. These facts support the need of therapeutic 
drug monitoring for dosage adjustment or treatment 
discontinuation, as needed. The development and implementation of 
a simple and rapid assay to quantify gemcitabine plasmatic 
concentrationsin clinical practice will contribute to the 
individualization of gemcitabine treatments.  
The quantification of gemcitabine plasmatic concentrationsusing an 
HPLC-UV method was previously described by others authors [3,9-
13,16-18]. Nevertheless, we verified in our laboratory the existence 
of complex steps to the sample preparation, resulting in high costs 
and unnecessary time consumption. Further more the application of 
those protocols under our laboratory conditions resulted in non-
satisfactory chromatograms, in terms of selectivity, accuracy and 
precision. 
Therefore, the aim of the present work was to develop, optimize and 
validate sensitive, specific, accurate, precise, reproducible, robust 
and rapid HPLC-UV method to quantify dFdC, in human plasma 
samples, according to the guidelines of the international regulatory 
institutions European Medicines Agency (EMA), US Department of 
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Health and Human Services – Food and Drug Administration (FDA) 
and International Conference on Harmonization (ICH). This method 
will then be applied to the quantification of gemcitabine plasmatic 
concentrations to apply in therapeutic drug monitoring in patients 
with advanced NSCLC undergoing combination therapy of 
gemcitabine and carboplatin. 
MATERIALS AND METHODS 
Materials and reagents 
Gemcitabine hydrochloride (2′ -Deoxy-2′,2′-difluorocytidine; 
C9H11F2N3O4·HCl) purity of ≥ 98% (HPLC) and Cytarabine  crystalline 
(4-amino-1-β-D-arabinofuranosyl-2(1H)-pyrimidinone; (C9H13N3O5) 
(internal standard, IS) were purchased from Sigma Aldrich (Sigma-
Aldrich Quimica, S. A., Sintra, Portugal). HPLC grade acetonitrile and 
methanol were purchased from Panreac Quimica Lda. (Cascais, 
Portugal) and triethylaminehydrochloride(TEA) ≥99% was acquired 
from Sigma Aldrich (Sigma-Aldrich Quimica, S. A., Sintra, Portugal). 
HPLC grade water was prepared in the laboratory using Milli-Q 
Ultrapure Water Purification System (Industrial Laborum Ibérica, 
SA, Braga, Portugal). All other reagents and solvents were of analytic 
or HPLC grade. Prior to use, mobile phase solvents were filtered 
using 0.45 µm filters and degassed in an ultrasonic bath for 15 min. 
Drug-free human plasma was obtained from healthy volunteers of 
the Porto Blood Regional Centre (Portuguese Blood Institute)and 
was used as a blank matrix. 
Equipment 
All HPLC runs were carried out using a LaChromUltra™ 
SystemAgilent (VWR International Lda, Carnaxide, Portugal), 
equipped with an organiser unit, two pumps L-2160U, a L-2200U 
auto-sampler, a L-2300 column oven, a L-2400 UV Detector and 
vacuum degasser. Results were acquired and processed with the EZ 
Chrom Elite™ Software (VWR International Lda, Carnaxide, 
Portugal). HPLC analysis was conducted with an ACE reversed-phase 
C18 column (ACE, Spain), with 5μm particle size, 4.6 mm internal 
diameters and 250 mm length. 
Chromatographic conditions 
Chromatographic analysis was performed in a gradient mode using 
two solvents (A and B). Solvent Aand solvent B consisted of sodium 
acetate bufferat pH 5 and acetonitrile, respectively. Initially, over 2 
minutes, the run were performed by an isocratic mode of 98.5:1.5 
(%A: %B) and then a linear gradient was ramped up from 1,5% to 
7% of solvent B in 3 min,and was maintained for 4 minutes. To 
restore working conditions, a linear gradient was applied at the 
initial solvents proportion in 2 minutes and maintained for 2 
minutes to ensure equilibrated analysis conditions in the next run. 
Total run time was 13 min and the mobile phase was pumped at a 
flow rate of 1 mL/min. Sample injection volume was 20 μl and the 
detection wavelength was 290 nm. All chromatographic runs were 
carried out in acolumn at 40ºC and samples placed in the auto-
sampler at 4ºC and protected from light. Ratios of total gemcitabine 
peak area/total cytarabine (IS) peak area was used to quantify 
gemcitabine concentrations. 
Preparation of stock and working solutions 
A stock solution of 100 mg/L of gemcitabine hydrochloride was 
prepared by weighing 5 mg of gemcitabine into a 50 mL volumetric 
flask and making up to volume with methanol. Seven working 
solutions (2.5, 5, 10, 25, 50, 75 and 100 mg/L were obtained by 
measuring the required amount of the 100 mg/L stock solution a 
completing with a sufficient amount of methanol up to 1 mL A stock 
solution of 100 mg/L of cytarabine (IS) was prepared using 5 mg of 
cytarabine crystalline and methanol, making a 50 mL solution. All 
stock and working solutions were stored at 4ºC until use. 
Preparation of standard solutions and quality controls 
Standard solutions (calibrators) comprising 0.25, 0.5, 1, 2.5, 5, 7.5 
and 10 mg/L were prepared in 1.5 mL polypropylene microtubes, by 
spiking 200 µL of blank human plasma with 100 µL of working 
solutions and 10 µL of IS stock solution.  
Then 650 µL of methanol were added to each microtube. Samples 
were then vortexed for 1 minute and centrifuged during 15 min at 
10500 rpm, at 4ºC. This step is taken to induce protein precipitation 
with the objective of eliminating potential interferences in the final 
chromatogram. After centrifugation, the supernatant (organic 
phase) is transferred to HPLC microvials for HPLC runs. 
Quality controls (QC) were prepared similarly, with the respective 
working solutions (2.5, 7.5, 45 and 80 mg/L). Zero samples were 
prepared by adding 50 µL of IS(100 mg/L) and 750 µL of Methanol 
to 200 µL of drug-free plasma and blank samplesby adding 800 µL of 
methanol to 200 µL of drug-free plasma and the protein 
precipitation carried out as explained above. All standard solutions 
and quality controls were prepared in ice and protected from light. 
Some aliquots were stored at −70ºC for stability tests.  
Validation methodology 
Bioanalytical method validation is essential in drug analysis because 
this process ensures that the analytical procedure employed for the 
analysis is suitable for its intended use and show reliability of the 
results produced [19-21].  
The current HPLC method was validated according to the EMA[21], 
FDA and to the ICH[20]guidelines.  
Accordingly to these guidelines, to ensure the acceptability of the 
performance and reliability of the analytical results, the following 
characteristics were considered: selectivity, carry-over, lower limit 
of quantification (LLOQ), detection limit (DL), calibration range, 
accuracy, precision, stability of the analyte in the biological matrix 
and stability of the analyte and of the internal standard in the stock 
and working solutions under the entire period of storage and 
processing conditions. 
A seven-point calibration curve was constructed by plotting the ratio 
of gemcitabine/IS peak areas (y) versus gemcitabine concentration 
(x) (carried out in triplicate) The concentration range for the 
calibration curve (0.25 to 10 mg/L) was defined according to the 
expected gemcitabine plasma concentrations [16,17]. Results for 
blank samples were not used as part of the calibration curve [21]. 
Gemcitabine standard solutions concentrations were then back 
calculated,using the calibration curve, and mean accuracy values 
were determined.  
Slope, intercept and linearity were determined by calculating the 
regression equation from the plot of peak area ratio vs 
concentration, for seven standard solutions (0.25, 0.5, 1, 2.5, 5, 7.5 
and 10 mg/l) using the linear least squares method [20], and by 
analysis of the respective response factors (i. e. peak area ratio 
divided by the concentration of each standard solution) [22,23]. 
The selectivity was demonstrated by the analysis of six blank 
plasma samples [21]. 
The carry-over was assessed by injecting of six blank plasma 
samples. After the injection of a high concentration standard 
solution (upper limit of quantification; ULOQ) [21]. 
The lower limit of quantification (LLOQ) is the lowest 
concentration of analyte in a sample, which can be reliably 
quantified, with acceptable accuracy and precision. The LLOQ signal 
should be at least 5 times the signal of a blank sample [21]. 
The detection limit (DL) is determined by the analysis of samples 
with known concentrations of analyte and by establishing the 
minimum level at which the analyte can be reliably detected [20]. 
The DL of our method was calculated using the following equation: 
DL = (3.3 σ)/ S, where σ is the standard deviation of the mean value 
resulting from analysis of an appropriate number (N=20) of blank 
samples and S is the slope of the calibration curve [20]. 
The accuracy was tested by calculating the percentage of the 
nominal value (relative error %) of four different gemcitabine 
concentrations (QC). The four QC used were (0.25, 0.75, 4.5 and 8.0 
mg/L). Accuracy was evaluated within a single run (within-run 
accuracy) and in different runs (between-run accuracy). Within-run 
accuracy was determined by analyzing, in a single run, a minimum of 
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5 samples per QC level. For the validation of the between-run 
accuracy, QC samples, from at least three runs, were analyzed on 
three different days [21,24]. 
The precision of the analytical method describes the closeness of 
repeated individual measures of analyte expressed as the coefficient 
of variation (CV) [24]. For precision determination, the QC samples 
were analyzed within a single run and in different runs, using the 
same runs and data as for the demonstration of accuracy [21]. 
Robustness was evaluated by deliberately varying the column 
temperature (± 5°C) and the detector wavelength (± 3 nm) 
[20,24,25]. 
Method applicability 
An analytical run consists of the blank sample (processed matrix 
sample without analyte and without IS) and a zero sample 
(processed matrix with IS), 6 calibration standards, 4 levels of QC 
samples (in duplicate), and study samples to be analyzed. As 
indicated before the calibration standards and QC samples should 
have been spiked independently using separately prepared stock 
solutions [21]. All samples were analyzed in triplicate, except when 
indicated otherwise. The optimized and validated method was used 
to quantify gemcitabine plasmatic concentrations in our study 
population to perform a pharmacokinetic study and to develop a 
pharmacokinetic/pharmacodynamic model to dose individualization 
in treatment scheme carboplatin/gemcitabine of NSCLC patients. 
RESULTS AND DISCUSSION 
Method development and optimization 
Prior to the validation step, the hereby-proposed method was 
developed to provide a simple and optimized procedure, with 
reduced time and analysis costs. For instance, we simplified some 
aspects related to sample preparation, proceeding to a one-step only 
protein precipitation. Moreover, several chromatographic 
performance parameters were considered, specifically, peak 
resolution (R), peak symmetry (described by the tailing factor, T) 
and the number of theoretical plates (N)[19,22,24].  
Initial runs were performed using similar mobile phases and 
internal standard as those used by other authors [3,9-13,16-18]. 
With the initial use of a mobile phase (MP) made up with phosphate 
buffer, pH 3/acetonitrile at a 98:2 ratio, phosphate crystals 
precipitation was observed. Therefore, to prevent collapse and 
damage of the column we substituted phosphate buffer pH 3 by 
sodium acetate buffer pH5, in the MP. This new MP was tested at 
various proportions, ranging from 90:10 to 99.5:0.5, using various 
flows and gradients. 
The gradient varying between 98.5:1.5 and 93:7 (Section 2.3 
Chromatographic conditions) was the most acceptable combination 
for the MP, allowing best peak resolution (>2) from the matrix 
compounds and good peak symmetry, as indicated by the obtained 
tailing factor values (0.8–1.2). These values are internationally 
accepted and indicate good method performance [19,24] 
In columns packaged with high silanol activity silica, the use of 
triethylamine (TEA) in MP remains a crucial step to improve peak 
symmetry [22,24,26]. Theoretically this addition can inhibit, or at 
least reduce, gemcitabine and cytarabine interaction with available 
acidic silanols, once these molecules contain amine groups in their 
chemical structure [22,24]. However, the column we used (ACE C18) 
has few acidic silanols available to cause peak tailing. These 
stationary phases are typically made with low activity silica (high 
purity "type B" silica) and have their surface highly covered by the 
bonded phase [26]. As such, in our working conditions, TEA was not 
added because this would probably provoke a new interfering peak 
in the chromatogram.  
Initially adenine was tested as the internal standard (IS). However, 
the poor chromatographic retention on reversed phase columns 
revealed to be a critical problem. Furthermore, we couldn’t separate 
adenine, with adequate resolution, from the solvent and from the 
gemcitabine peak. Therefore, we decided to substitute cytarabine by 
adenine and good resolutions (>2)were then obtained both for 
gemcitabine and solvent. The resulting chromatographic 
performance parameters of the chosen setup for validation are 
presented in Table 1. 
 
Table 1: Chromatographic performance parameters of the chosen setup 
Chromatographic parameters  Resulta Acceptance criteria 
Gemcitabine retention time (min) 8.33±0.05 - 
Cytarabine retention time (min) 5.27±0.05 - 
Gemcitabine resolution, R G 8.73±0.50 > 2 
Cytarabine resolution, R IS 2.48±0.08 > 2 
Gencitabine Tailing factor, T G 1.03±0.10 0.8 - 1.2 
Cytarabine Tailing factor, T IS 1.01±0.04 0.8 - 1.2 
Gemcitabine Number of theorical plates, N G 18522.57±4770.89 N > 2000 
Cytarabine Number of theorical plates, N IS 2273.75±240.65 N > 2000 
a Presented as mean value ± standard deviation (SD).  
 
Although the maximum absorption of gemcitabine has been 
reported to occur at 272 nm[27], as confirmed by others authors 
[10,11,17,18], we tested a UV wavelength range between 250 and 
300 nm. The best detection was verified at a wavelength of 290 nm, 
where the noise signal was in fact small. The highly polar nature of 
the analytes causes a rapid elution from reversed-phase columns 
[24] even with a very low (1%) organic content in the MP.  
Therefore, several columns were tested (ACE C18 (250x4.6 mm, 
5 μm particle size), Symmetry C8 (250x4.6, 5 μm particle size) and 
Waters Spherisorb® C18 ODS2 (150x4.6, 5 μm particle size)) and 




The method selectivity was evaluated by comparing the 
chromatograms of six blank plasmas to the chromatogram of the 
calibrator used to determine the LLOQ (0.25 mg/L) and to the 
chromatogram of the stock solution of cytarabine (50 mg/L). No 
peaks at the retention time of gemcitabine (8.33 min) and cytarabine 
(5.27 min) were observed (fig. 2) and a representative 
chromatogram showing the separation of the analytes from the 
matrix is shown in fig. 3. 
 
 
Fig. 2: Representative chromatograms of human blank plasma. 
Fresco et al. 






Fig. 3: Representative chromatograms of human plasma with 
internal standard (IS) and gemcitabine standard solution 
5mg/L. 
 
The peak observed at 12 minutes is resultant of the matrix. Most 
probably being plasmatic proteins since that peak was also present 
in the blank plasma samples. As acceptance criteria, the absence of 
interfering components was validated when the signal is lower than 
20% of the LLOQ for the analyte and 5% for the IS. The results 
obtained are presented in table 2. Overall, obtained data provides 
evidence that the method can be regarded as selective since no 
potential interfering peaks were observed. 
Carry-over 
Carry over was not detectable in six blank samples, analyzed after 
the higher concentration standard solution. Carry over absence 
criterion: noise signal of the blank plasma should be lower than 20% 
of the LLOQ and lower than 5% of the IS. Obtained results are 
presented in table 3. 
 
Table 2: Gemcitabine and cytarabine selectivity data 
Gemcitabine Selectivity 
 LLOQ (0,25mg/L) area 20% of LLOQ area Blank area Result 
Mean Value (N=6) 5167.50 1033.50 657 < 20% 
Cytarabine (Internal Standard) Selectivity 
 IS area 5% of IS area Blank area Result 
Mean Value (N=6) 129196.33 6459.82 16 < 5% 
LLOQ: Lower Limit of Quantification 
 
Table 3: Gemcitabine and Cytarabine carry-over data 
Gemcitabine Carry-over 
 LLOQ (0,25mg/L) Area 20% of LLOQ Area Blank Area Result 
Mean Value (N=6) 5167.50 1033.50 627.17 < 20% 
Cytarabine (Internal Standard) Carry-over 
 IS Area 5% of IS Area Blank Area Result 
Mean Value (N=6) 129196.33 6459.82 25.17 < 5% 
LLOQ: Lower Limit of Quantification 
 
Lower Limit of Quantification (LLOQ) and Detection Limit (DL)  
The lowest concentration at which an analyte can be detected (DL) 
or quantified with adequate accuracy and precision (LLOQ) can be 
determined by different approaches [20]. In the present study, the 
LLOQ was firstly defined according to the expected plasmatic 
concentrations. As the acceptance criterion for LLOQ gemcitabine 
signal, that should be at least 5 times the signal of a blank 
sample[21]. The DL was calculated from the standard deviation (SD) 
of the mean value obtained from the analysis of 20 blank samples 
and the slope of the calibration curve, as previously described (2.7. 
Validation Methodology). LLOQ and DL were defined as 0.25 and 
0.22 mg/L, respectively. 
Calibration range 
In the construction of the calibration curve, seven standard solutions 
(0.25, 0.5, 1, 2.5, 5, 7.5 and 10 mg/L) were analyzed: four different 
runs carried out in triplicate, in four consecutive days. The linear 
regression of the ratio of the analyte area to that of IS, versus 
gemcitabine concentration was used. The mean equation (N=4) of 
the calibration curve obtained from media of those seven points was  
1) y = 0.1599(±0.0023)X -0.019 (±0.0117). R 
Where
2=0.9998 
 y is the ratio gemcitabine peak area /IS peak area and X is the 
gemcitabine concentration in mg/L. Mean and SD values 
for y and X 
Linearity 
are indicated inside brackets.  
Firstly, linearity was studied in the concentration range of 0.25 – 
10 mg/L by visual inspection of the calibration curve plotting (fig. 4) 
and then by calculating the coefficient of determination (squared 
correlation coefficient: R2)by the least squares method[23]. Good 
linearity was considered whenR2 higher than 0.999 were obtained, 
accordingly to what is internationally accepted[19,24]. In addition, 
linearity of the regression line was evaluated by a procedure based 
on the residual sum of squares: taking the regression line as the 
mean, a RSD was calculated for all data points, revealing values 




Fig. 4: Linearity studies for the proposed HPLC method: 
calibration curve obtained with gemcitabine standard solutions 
(N=7) 
Although these are very practical ways of evaluating linearity data, 
they are not true measures of linearity. The coefficient of correlation 
can be subject of misinterpretation and may give a 
misrepresentation of linearity, since different datasets can yield 
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identical regression statistics and should be reinforced by 
complementary linearity evaluation methods [19,22,25].  
As such, an analysis of response factors (ratio gemcitabine peak area 
/IS peak area divided by the concentration of each standard 
solution) for the proposed range was also carried out. The visual 
inspection and linear regression by the method of least squares of 
the plot of the response factors versus concentration of standard 
solutions (fig.5) revealed a near zero slope (0.0042), thus reinforcing 
the evaluation of the method as linear [22,25]. 
 
 
Fig. 5: Linearity studies for the proposed HPLC method: 
response factor versus gemcitabine standard solutions 
concentration (N=7). 
 
Back Calculated Concentrations 
The back calculated concentrations, represents the first point of 
control during the bioanalytical method validation. This procedure, 
involving the standard solutions is useful to validate or reject some 
points of the concentration range used. In the table 4 are indicated, 
in terms of accuracy the relative error(RE%) of the back-calculated 
concentrations of the standard solutions used in the calibration 
curve. All back calculated concentrations satisfied the acceptance 
criterion: ±15% of the nominal value, except for the LLOQ for which 
it should be within ±20% interval; at least 75% of the standard 
solutions must fulfill this criterion[21]. 










0.25 0.30 -18.12 <20% 
0.5 0.52 -4.03 <15% 
1 0.94 6.12 <15% 
2.5 2.57 -2.76 <15% 
5 4.82 3.69 <15% 
7.5 7.41 1.25 <15% 
10 10.03 -0.28 <15% 
 
Accuracy 
Accuracy is the closeness in agreement of the nominal true value to 
the determined value obtained by method developed, by calculating 
the percentage recoveries of the mean concentration of the analyte 
at four different concentrations. The four quality controls (QC) (0.25, 
0.75, 5 and 7.5 mg/L) were carefully prepared in the same way 
standard solutions were.  
In table 5results for the within run accuracy (N=5) and in table 
6results for the between-run accuracy (N=3) shows close agreement 
between experimental and nominal values, fulfilling the 
internationally recognized acceptance criterion: the mean 
concentration should be within 15% of the nominal values for the 
QC samples, except for the LLOQ which should be within 20% of the 
nominal value [21]. 
Precision 
Method precision is a measure of the ability of the method to 
generate reproducible results. Precision was validated for within-
run and between-run, in terms of coefficient of variation (CV, %) as 
demonstrated in table 5 and 6, respectively. These results indicate 
that the developed and optimized HPLC method presents good 
precision, since it fulfills the internationally recognized acceptance 
criterion: CV values should not exceed 15% for the QC samples, 
except for the LLOQ which should not exceed 20%[21]. 
 
Table 5: Within-run Accuracy and within-run Precision data 
QC (mg/L) Media measured concentration (mg/L) (N=5) RE(%) Result CV (%) Result 
0.25 0.28 -11.69 <20% 8.66 <20% 
0.75 0.72 3.74 <15% 3.74 <15% 
4.5 4.24 5.76 <15% 1.6 <15% 
8 7.77 2.83 <15% 2.57 <15% 
QC: Quality control; RE: Relative error; CV: Coefficient of variation  
 
Table 6: Between-run accuracy and between-run precision data 
QC (mg/L) Media measured concentration (mg/L) (N=3) RE(%) Result CV (%) Result 
0.25 0.29 -16.51 <20% 6.52 <20% 
0.75 0.72 3.91 <15% 3.52 <15% 
4.5 4.19 6.95 <15% 0.78 <15% 
8 7.87 1.59 <15% 3.41 <15% 
QC: Quality control; RE: Relative error; CV: Coefficient of variation 
 
Stability 
The stability of gemcitabine and IS was tested under conditions similar 
to those that would be employed for the sample in a real time analysis.  
Following the validation requirements for bioanalytical methods, we 
evaluated: the stability of stock solutions (gemcitabine and 
cytarabine) during 24h over analysis conditions (in auto-sampler at 
4ºC and protected from light), and also was evaluated the mobile 
phase stability after 1 week at room temperature. Since, cytarabine 
cannot be stored at room temperature (storage temperature: 2-8ºC), 
the implementation of this test in our working conditions, have not 
applicability. 
To validate the storage conditions of the real samples, was evaluated 
the stock solutions stability frozen at −70ºC over  4 weeks, and 
refrigerated at 4ºC over 4 weeks, by preparing working solutions 
from the stock solutions stored at those conditions.  At the 
respective times, these tests were performed by preparing in 
triplicate the lower (0,25mg/l) and the higher (8 mg/l) QC.  
Accuracy results (table 7), indicated as RE(%),demonstrates that 
the HPLC method developed shows good stability and can be used to 
analyze fresh and frozen samples, once it fulfilled the international 
acceptance criteria (RE%<2%) [19]. Other authors have also 
demonstrated gemcitabine stability when stored at room 
temperature up to 6 days[3,9] and at −70ºC for up to 2 years [9]. 
 
 
Table 7: Stability results for gemcitabine and cytarabine stock solutions by preparing the lower and the higher quality controls. 
Stock solution stability refrigerated at 4º over 1 month 
QC Media (N=3) RE % 
0.25 0.25 1.73 
8 8.05 -0.62 
Stock solution stability frozen at -70ºC over 1 month 
QC Media (N=3) RE % 
0.25 0.25 0.37 
8 7.93 0.82 
Sample stability at the auto-sampler working conditions at 4ºC over 24h 
QC Media RE % 
0.25 0.25 -0.30 
8 7.96 0.45 
Mobile phase stability at room temperature over 1 week 
QC Media RE % 
0.25 0.25 -1.58 
8 7.98 0.31 
 
Robustness 
Robustness is a measure of the performance of a method to remain 
unaffected when small and deliberate changes are made. This 
characteristic provides an indication of the method reliability during 
normal usage. The intent of robustness validation is to identify 
critical parameters for the successful implementation of the method. 
Robustness was partially evaluated during method development, 
when important conditions (e. g., peak shape, sensitivity) was 
optimized to improve method performance[20,22,25]. In this study, 
we tested deliberated variations in column temperature (±5°C) and 
in detect or wavelength (±3 nm). These method variations did not 
reveal differences greater than ±15% of the nominal value for 
quality controls tested when method working conditions changes ± 
5ºC in oven temperature and with detection at 287 nm (-3 nm) 
(table 8). Relatively to peak characteristic, namely resolution, tailing 
factor and the number of theoretical plates were similar to the initial 
and validated conditions, respectively 4.16, 1.03 and 2648 to 
cytarabine peak and 8.73, 1.05 and 21768 to gemcitabine peak. On 
the other hand, when varying the wavelength detection to 293, we 
obtained unacceptable relative errors (around 20%) as reflex of 
poor peak.  
At this wavelength we verified a drastically variation on area ratios 
and we conclude that the absorption of gemcitabine decrease 
disproportionally to cytarabine. Furthermore, 290 nm is a great 
wavelength to eliminate interfering compounds but reduces 
significantly the method sensibility. 
 
Table 8: Robustness tests data. 
Robustness – Oven temperature at 35ºC and detection at 287 nm 
QC (mg/l) Media (N=3) RE % 
0.25 0.28 -10.63 
0.75 0.78 -4.28 
4.5 4.58 -1.72 
8 8.05 -0.73 
Robustness – Oven temperature at 45ºC and detection at 287 nm 
QC (mg/l) Media (N=3) RE % 
0.25 0.25 1.78 
0.75 0.76 -1.39 
4.5 4.55 -1.18 
8 8.21 -2.62 
 
CONCLUSION 
The bioanalytical method described, based on arapid and simple 
sample preparation (protein precipitation) and HPLC-UV 
determination, allows the quantification of gemcitabine in human 
plasma. The optimized RP-HPLC method was fully validated 
according to the EME, FDA and ICH guidelines. It was demonstrated 
to be selective, linear, accurate, precise, stable and robust in the 
range of 0.25–10 mg/L. Also, the DL and the LLOQ were determined. 
The method represents a suitable and useful tool for the analysis of 
gemcitabine plasmatic concentrations in pharmacokinetic/ 
pharmacodymanic studies in NSCLC patients to perform dose 
individualization of the treatment schemes. 
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